Trials / Completed
CompletedNCT03489200
EH301 for the Treatment of ALS
EH301 for the Treatment of Amyotrophic Lateral Sclerosis: a Placebo-Controlled Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Elysium Health · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this trial is to evaluate the efficacy and tolerability of EH301 in patients with amyotrophic lateral sclerosis. Patients with ALS are randomized to receive either EH301 or placebo daily and undergo active evaluation for 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | EH301 | 1-(beta-D-Ribofuranosyl)nicotinamide chloride and 3,5-Dimethoxy-4'-hydroxy-trans-stilbene |
| OTHER | Placebo | No intervention- placebo |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2018-04-05
- Last updated
- 2018-05-18
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT03489200. Inclusion in this directory is not an endorsement.